Zeno Pathology
| Solution Type | AI Suite/Add-on |
|---|---|
| Deployment Environment | Clinical Diagnostics |
| Regulatory Clearance | Breast Cancer (Her2) – CE-IVD, Breast Cancer (Ki-67) – CE-IVD, Breast Cancer (Metastatic Detection) – CE-IVD |
| Target | Breast Cancer |
| Platform Dependency | Requires Specific Platform |
| Deployment Options | Hybrid (Cloud analysis, local viewer) |
Be the first to review “Zeno Pathology” Cancel reply
Have you considered:
Compare Solutions
No products to compare
Get Pathology News Delivered to Your Inbox
News
Editor2026-08-17T09:19:14+00:00
Open-Source Platform Brings High-Resolution Spatial Biology Within Reach of Smaller Labs
Editor2026-08-17T09:19:14+00:00August 17, 2026|
Editor2026-08-14T06:48:56+00:00
Techcyte and elea Bring AI-Native Pathology Reporting into Techcyte FusionⓇ
Editor2026-08-14T06:48:56+00:00August 13, 2026|
Editor2026-08-13T08:46:16+00:00
Pathologic Characterization of Non-Mass Enhancement Lesions of the Breast in MRI-guided Biopsy
Editor2026-08-13T08:46:16+00:00August 13, 2026|
Editor2026-08-14T06:49:00+00:00
OnePath Diagnostic Now Runs on elea’s AI-Native Pathology Operating System
Editor2026-08-14T06:49:00+00:00August 13, 2026|
Editor2026-08-12T08:47:23+00:00
A multisite survey on patient perspectives of breast cancer risk assessment and supplemental breast cancer screening tools
Editor2026-08-12T08:47:23+00:00August 12, 2026|
Editor2026-08-10T07:51:40+00:00
Keeping Digital Pathology Open: The Regulatory Framework Behind Concentriq AP-Dx
Editor2026-08-10T07:51:40+00:00August 12, 2026|
Editor2026-08-11T14:54:03+00:00
Lumea Climbs the 2026 Inc. 5000 Ranking, Reflecting Continued Rapid Growth
Editor2026-08-11T14:54:03+00:00August 11, 2026|






















Reviews
There are no reviews yet.